A Science and Technology Blog
The Recovery Trial will test five already approved drugs — HIV drug Lopinavir-Ritonavir, anti-inflammatory corticosteroid (dexamethasone), anti-malaria drug hydroxychloroquine and antibiotic azithromycin — on COVID-19 patients. It will also test…
ICMR’s insistence on an evidence-based approach to plasma therapy is a welcome change and is in stark contrast to the cavalier manner in which it approved hydroxychloroquine as a prophylaxis…
A ribonucleoside analog (β-D-N4-hydroxycytidine or NHC) that was previously shown to be effective against influenza and Ebola is also potent against coronaviruses, including the novel coronavirus. The prodrug of NHC…
Treating severe COVID-19 patients with the antiviral drug remdesivir does not quicken recovery, the first randomised, placebo-controlled, double-blind trial found. Although not statistically significant, those treated with the drug within…
Results of a randomised, control trial using hydroxychloroquine drug in 150 COVID-19 patients show that the drug does not reduce the viral load even on day 28. However, patients who…
About 30% of patients with mild symptoms failed to develop high amounts of neutralising antibodies even after recovering from COVID-19 disease. If natural infection with novel coronavirus does not elicit…
Given the circumstances, it would be difficult to believe that the decision to lift the restriction was taken independent of U.S. pressure. But the pandemic has seen several countries displaying…
The journal that published a paper claiming that hydroxychloroquine had “significant” success in treating COVID-19 patients now has an expression of “concerns” published by its publisher. On March 23, ICMR…
